The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Background Rivaroxaban and apixaban are two direct oral anticoagulants (DOACs) targeting Factor Xa. Each DOAC was separately proven effective and safe when compared to standard treatment (heparin followed by warfarin) in patients diagnosed with venous thromboembolism (VTE). Several retrospective coh...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.4927-4927
Hauptverfasser:	Ouyang, Haoxu, Khillan, Ratesh, Yu, Nyein Htway, Preet, Mohan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!